Skip to main content

Table 2 Effect of carboplatin on pCR according to HER2 status

From: The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

HER2 Status

Carboplatin

pCR (-)

pCR (+)

p

HER2-zero

Non-Recipient

53 (60.9%)

34 (39.1%)

0.021ˣ2

 

Recipient

11 (36.7%)

19 (63.3%)

 

HER2-low

Non-Recipient

92 (80.7%)

22 (19.3%)

0.028ˣ2

 

Recipient

24 (63.2%)

14 (36.8%)

 
  1. Statistical Test: ˣ2Chi-square test
  2. Abbreviation: pCR Pathological Complete Response
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us